Multiple Myeloma Patient and Caregiver Survey: XVd - selinexor + bortezomib + dexamethasone |
Introduction
We need your help!
Selinexor (Xpovio) in combination with bortezomib (Velcade) and dexamethasone (XVd) will soon be re-reviewed for reimbursement by the Institut national d’excellence en santé et en services sociaux (INESSS), in patients with relapsed/refractory myeloma who have received at least two prior lines of therapy.
Myeloma Canada is contributing additional patient and caregiver input to the INESSS re-review process in the hope that the Quebec myeloma community may have equal access to this treatment, which was approved for reimbursement by pCODR in 2022. Sharing your experiences with decision-makers helps them better understand how selinexor (XPOVIO) treatment could benefit those impacted by myeloma.
This survey is open to all individuals with myeloma and/or their caregivers
As always, your input is extremely important and helps further our goal of improving Canadians' access to new myeloma treatments.
The survey should only take around 10 minutes of your time. We ask that the survey please be completed by December 9, 2024, 11:59 PM EST.
As always, your input is extremely important and helps further our goal of improving Canadians' access to new myeloma treatments.
The survey should only take around 10 minutes of your time. We ask that the survey please be completed by December 9, 2024, 11:59 PM EST.
If you have any questions, please write to contact@myeloma.ca and indicate “Drug Survey” in the subject line.
Thank you in advance for your participation and helping others impacted by myeloma!
Privacy policy: All survey datum is collected by Myeloma Canada. To ensure patient and caregiver privacy and confidentiality, individual responses will not be identifiable. Please note selected quotations may be used in the final reports without reference to any identifying information.